Philip Lowry, MD

Guthrie Provider

Specialties:

Hematology
Medical Oncology
Care Provider Overall: 
5
Provider Reviews: 
100
  • Facebook logo
  • Twitter logo
  • Print Mail logo
  • Print HTML logo

View Locations

  • Clinical Details
  • Education
  • Clinical Trials
Hospital Privileges: 
  • Guthrie Robert Packer Hospital
Clinical Interests: 
  • Colorectal Cancer
  • Lung Cancer
  • Telemedicine

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of Recommending Care Provider: 
5
Patients' Confidence in Care Provider: 
5
Time Care Provider Spent with Patient: 
5
Care Provider Spoke Using Clear Language: 
5
Care Provider Efforts to Include in Decisions: 
5
Care Provider's Concern for Questions and Worries: 
5
Care Provider's Explanations of Condition/Problem: 
5
Care Provider Information About Medications: 
5
Care Provider Instructions for Follow-Up Care: 
5
Care Provider's Friendliness and Courtesy: 
5
Residency: 
  • University of Virginia, Charlottesville, Va.
Certification: 
  • American Board of Internal Medicine/Hematology
  • American Board of Internal Medicine/Oncology
Education: 
  • Yale University School of Medicine, New Haven, Conn.
Fellowship: 
  • University of Virginia, Charlottesville, Va.
Department: Oncology
Diagnosis: Genito-urinary - Prostate
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT03419234
Title: EA8153 Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SWOG
Details (Identifier #): NCT03851445
Title: LungMap (Screening Protocol for Lung-Map):
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02465060
Title: MATCH EAY131, Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: MacroGenics
Details (Identifier #): NCT02492711
Title: MacroGenics SOPHIA, CP-MGAH22-04, A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: Mirati
Details (Identifier #): NCT02219711
Title: Mirati 516-001: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02750826
Title: Alliance A011401, Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: NRG
Details (Identifier #): NCT02488967
Title: NRG-BR003: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02927249
Title: A011502, A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Department: Oncology
Diagnosis: Genito-urinary - Miscellaneous
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: NCI
Details (Identifier #): NCT02502266
Title: NRG-GY005,A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02193282
Title: A081105, Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Head and Neck
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: NRG
Details (Identifier #): NCT03258554
Title: NRG-HN004 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02194738
Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SWOG
Details (Identifier #): 03373760
Title: S1400F:A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT03633331
Title: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SWOG
Details (Identifier #): NCT02595905
Title: S1416, Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: Roche
Details (Identifier #): NCT03135262
Title: BH39147, A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Idasanutlin and Venetoclax in Patients with Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination with Idasanutlin and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SWOG
Details (Identifier #): NCT03418961
Title: S1501, Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: BMS
Details (Identifier #): NCT02869789
Title: BMS CA209-817, A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SynCore
Details (Identifier #): NCT03126435
Title: CT4006: A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02201992
Title: E4512, A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02445391
Title: EA1131, A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02595944
Title: EA5142, Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02224781
Title: EA6134:DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing); A Phase III Trial

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Guthrie Patient: February 2019
*Dr. Lowry and his staff truly demonstrate Guthrie values. Very professional department.
Guthrie Patient: February 2019
*Dr. Lowry always goes the extra mile for his patients - He is a tremendous asset to Guthrie.
Guthrie Patient: February 2019
He is the best.
Guthrie Patient: December 2018
I have already recommended Dr Lowry to several people.
Guthrie Patient: December 2018
Dr. Lowry is just the best. Dealing with a cancer scare this Fall, Dr. Lowry and his staff have been so kind and understanding. Dr. Lowry always communicates in a way that is honest, yet also compassionate and caring. His gentle sense of humor always leaves me smiling, even during tough times. I cannot thank Dr. Lowry enough for his knowledge, professionalism, and care.
Guthrie Patient: December 2018
I cannot tell you have relieved I am to now have Dr. Lowry as my oncologist. There has been a great deal of transition in the Guthrie oncology department over the past couple years. After 4 different oncologists, I had been seriously considering no longer coming to Guthrie. That is no longer being contemplating. Dr. Lowry was brilliant. First, he reviewed my cancer history and treatment with me. I had concerns related to medication and bone lose and he responded with a plan to deal with both issues. He explained what he wanted to do and why. He provided me with more information on self examination than I had been given previously. The past few times I left Guthrie I had more concerns after the visit than before. This time I left with the sense I was in the hands of an extremely competent and knowledgeable doctor. Simply stated, he alleviated my concerns and substantially reduced my level of stress. And he has a terrific bedside manner and sense of humor. Thank you so much Dr. Lowry.
Guthrie Patient: December 2018
Always have questions and concerns. Often more after we leave the appt, then email those concerns/questions and they are replied to.
Guthrie Patient: December 2018
good
Guthrie Patient: October 2018
Doctor was straight forward. did a great job of explaining my option. And why he made the recommendation he made
Guthrie Patient: October 2018
He is a very good doctor and we have confidence in him. He is knowledgeable and he is willing to work through solutions to the health and care of my husband.